

Diabetes Mellitus Significantly Increases Trauma Associated Complications and Utilization of Resources

Matthew J. Delano, M.D., Ph.D.

Assistant Professor of Surgery
University of Michigan

October 11th, 2016

Disclosures

- ◆ No Conflicts of Interest
- ◆ No Financial Disclosures

“To give anything less than your best is to sacrifice the gift.”

-Steve Prefontaine

Trauma Health Care Burden

Trauma accounts for 41 million ED visits and 2.3 million hospitalizations yearly

Life Years Lost¹ (2010, most recent available)

- Trauma injury accounts for 30% of all life years lost in the U.S.
- Cancer accounts for 16%
- Heart disease accounts for 12%

Economic Burden²

- \$585 billion a year, including both health care costs and lost productivity

Deaths due to injury³ (2010, most recent available) - 192,000

Ranking as cause of death³

- #1 for age group 1-46, or 47% of all deaths in this age range
- #3 as leading cause of death overall, across all age groups

Falls⁴ (2009, most recent available)

- 8 million people were treated in the ED for nonfatal injuries related to falls
- 2.2 million were people aged over 65 years with substantial comorbidities
- In 2008 over 19,700 people died of fall-related injuries; over 17,700 > 65 years old

¹ Life Years Lost: A measure to account for the age at which deaths occur, giving greater weight to deaths occurring at younger ages and lower weight to deaths occurring at older ages. The LYL (percentage of total) indicator measures the LYL due to a particular cause of death as a proportion of the total LYL lost due to premature mortality in the population. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS) [online]. Accessed February 17, 2014.

² Finkelstein, E.A., Corso, P.S., & Miller, T.R. The Incidence and Economic Burden of Injuries in the United States. USA: Oxford University Press. 2006

³ Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS) [online]. Accessed February 17, 2014.

⁴ <http://www.cdc.gov/HomeandRecreationalSafety/Falls/adultfalls.html>

Obesity and Severe Injury

- ◆ Increased body weight and the risk for human disease is a major health concern
- ◆ The National Institutes of Health has classified individuals according to body mass index (BMI) to assess population-wide risks for comorbid diseases

NIH/WHO Body Mass Index Classifications

| Class | Body Mass Index (kilogram/meter ²) |
|----------------|--|
| Underweight | <18.5 |
| Normal Weight | 18.5–24.9 |
| Overweight | 25–29.9 |
| Obese | 30–39.9 |
| Morbidly Obese | ≥ 40 |

Obesity and Severe Injury

◆ Outcome differences between obese and nonobese patients following severe injury

| | Normal Weight (n = 173) | Overweight (n = 152) | Obese (n = 101) | Morbid (n = 29) | p |
|--|-------------------------|----------------------|-----------------|-----------------|------|
| Any nosocomial infection | 41.0 | 48.0 | 42.6 | 62.1 | .150 |
| Pneumonia | 26.6 | 28.1 | 26.7 | 31.0 | .958 |
| Bloodstream infection | 8.1 | 15.0 | 19.8 | 13.8 | .043 |
| Urinary tract infection | 17.9 | 12.4 | 14.9 | 34.5 | .028 |
| Catheter-related bloodstream infection | 2.9 | 3.9 | 5.0 | 10.3 | .301 |
| Ventilator-associated pneumonia | 25.9 | 23.7 | 25.7 | 20.7 | .915 |

Nosocomial Infections (%)

| | Normal Weight (n = 173) | Overweight (n = 152) | Obese (n = 101) | Morbid (n = 29) | p |
|-------------------------------------|-------------------------|----------------------|-----------------|-----------------|-------|
| Any noninfectious complication | 36.4 | 38.8 | 46.5 | 58.6 | .078 |
| Acute respiratory distress syndrome | 20.2 | 21.1 | 27.7 | 41.4 | .053 |
| Cardiac arrest | 2.3 | 2.6 | 2.0 | 17.2 | <.001 |
| Myocardial infarction | 0.0 | 1.3 | 1.0 | 3.4 | .253 |
| Cerebral infarction | 2.9 | 2.0 | 3.0 | 0.0 | .765 |
| Deep vein thrombosis | 5.2 | 5.9 | 6.9 | 6.9 | .941 |
| Pulmonary embolism | 2.3 | 3.9 | 3.0 | 3.4 | .868 |
| Rhabdomyolysis | 1.2 | 5.2 | 4.0 | 10.3 | .053 |
| Acute renal failure | 1.2 | 0.0 | 2.0 | 10.3 | <.001 |
| Multiple organ failure | 43.9 | 46.7 | 58.4 | 72.4 | .008 |

Noninfectious Complications (%)


Obesity and Severe Injury

◆ Study Conclusions:

- Complications increase with increasing BMI
- Independent associations exist between BMI and morbidity
- BMI-related increases in MOF including longer intensive care unit stays, greater number of ventilator days, cardiac arrests, and episodes of acute renal failure

Obesity and Severe Injury

- ◆ What is/are the underlying mechanism(s) responsible for obesity related elevations in MOF and complicated outcomes?



Obesity and Severe Injury

- ◆ Obese patients received greater resuscitation volumes per actual body mass, however this difference abated when volumes were adjusted for lean and ideal body mass
- ◆ **Study Conclusions Obese Patients:**
 - Morbidly obese patients show prolonged metabolic acidosis in severe blunt trauma
 - The prolonged metabolic acidosis is attributed to suboptimal resuscitation endpoints combined with underlying metabolic abnormalities



Type 2 Diabetes (T2D)

- ◆ 29 million people in the USA have diabetes of all types
- ◆ T2D comprises well over 90% of the total diabetic population (over **27 million now in the USA**)
- ◆ Over **50 million Indians** have T2D now (over 79 million by year 2030)
- ◆ **With increases in the prevalence of advanced age, obesity, poor diet, and inactivity the incidence of T2D is expected to rise dramatically**

Chen, L. *et al.* (2011) *Nat. Rev. Endocrinol.* doi:10.1038/nrendo.2011.183.

Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. *AMJ* 2014, 7, 1, 45-48.

Epidemiology T2D Present and Future



Chen, L. *et al.* (2011) *Nat. Rev. Endocrinol.*
doi:10.1038/nrendo.2011.183



T2D and Trauma

- ◆ Hyperglycemia is associated with complications and worsened outcome among trauma victims
- ◆ Rapid expansion of the elderly and obese populations has increased the prevalence of T2D in trauma patients
- ◆ **Hypothesis: The presence of T2D is associated with poor outcomes among trauma patients**

Kao, LS, Todd, R, Moore, FA, The impact of diabetes on outcome in traumatically injured patients: an analysis of the National Trauma Data Bank. *The American Journal of Surgery* 192 (2006) 710–714

McGwin G Jr, MacLennan PA, Fife JB, et al. Preexisting conditions and mortality in older trauma patients. *J Trauma* 2004;56:1291– 6.

Laird AM, Miller PR, Kilgo PD, et al. Relationship of early hyperglycemia to mortality in trauma patients. *J Trauma* 2004;56:1058–62.

Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycemia as a prognostic indicator in trauma. *J Trauma* 2003;55:33– 8.

Bochicchio GV, Sung J, Joshi M, et al. Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. *J Trauma* 2005;58:921– 4.

Materials & Methods

- ◆ Michigan Trauma Quality Collaborative data analyzed from 2012-2014 (~ 35,000 patients).
- ◆ Patients with no signs-of-life, Injury Severity Score < 5, age < 18 years, and hospitalization < 1 day were excluded.
- ◆ Multivariable logistic or linear regression was used to compare patients with and without T2D.
- ◆ Variables utilized in risk-adjustment include demographics, physiology, comorbidities, and injury scoring.
- ◆ Results were confirmed using propensity score matching.

Patient Characteristics

Table 1.

| | No Diabetes (n=30,473) | Diabetes (n=4,238) | p-value |
|--------------------------|---------------------------|-----------------------|---------|
| Age | 51.4 + 22.8 | 68.6 + 15.5 | <0.001 |
| Male | 64.7% | 55.9% | <0.001 |
| ISS | 12.8 + 8.7 | 12.1 + 7.3 | <0.001 |
| Race (Non-White) | 26.2% | 17.2% | <0.001 |
| Congestive Heart Failure | 2.3% | 8.4% | <0.001 |
| PVD | 0.3% | 1.3% | <0.001 |
| Hypertension | 28.6% | 73.5% | <0.001 |
| Dialysis | 0.5% | 3.3% | <0.001 |
| Cirrhosis | 0.5% | 1.2% | <0.001 |
| Metastasis | 0.3% | 0.5% | 0.0111 |
| Active chemotherapy | 0.2% | 0.4% | 0.0024 |
| Acquired coagulopathy | 6.9% | 18.9% | <0.001 |
| Obesity | 10.2% | 23.8% | <0.001 |
| Ascites | 0.1% | 0.3% | 0.0005 |
| Drug use | 10.6% | 4.1% | <0.001 |
| Smoker | 27.1% | 14.8% | <0.001 |
| Psych | 10.0% | 9.9% | 0.8673 |
| Anticoagulated | 8.7% | 23.1% | <0.001 |
| Blunt Mechanism | 90.7% | 98.0% | <0.001 |
| Transfer | 19.7% | 21.0% | 0.041 |

Selected Outcomes Analyzed

Table 2.


Complications:

| | |
|----------------------|--|
| Infection | Incisional SSI Organ Space SSI UTI Pneumonia C. Diff Systemic sepsis |
| Cardiac | Cardiac arrest requiring CPR MI |
| Renal | Acute renal failure |
| Venous Throm. | PE DVT - LE DVT - UE |
| Other | Wound Disruption Abdominal fascia left open ARDS Unplanned intubation Stroke/CVA Abdominal compartment syndrome Extremity compartment syndrome Decubitus ulcer Enterocutaneous fistula |

Propensity Score Matching

Matching Variables

Age
 Age²
 Sex
 ISS
 ISS²
 GCSM (categories)
 Pulse (categories)
 BP (categories)
 Race
 Mechanism of injury (Blunt)
 Transfer
 Congestive Heart Failure
 PVD
 Hypertension
 Dialysis
 Cirrhosis
 Metastasis
 Active chemotherapy
 Acquired coagulopathy
 Obesity
 Ascites
 Drug use
 Smoker
 Psych
 Anticoagulated



| Sample | Ps R2 | LR chi2 | p>chi2 | MeanBias | MedBias | B | R | %Var |
|-----------|-------|---------|--------|----------|---------|--------|-------|------|
| Unmatched | 0.186 | 4795.03 | 0.000 | 19.5 | 9.9 | 125.4* | 0.49* | 100 |
| Matched | 0.002 | 21.51 | 0.973 | 1.2 | 1.1 | 10.1 | 1.10 | 40 |

T2D Negatively Impacts Trauma Outcomes

- ◆ Univariate comparison of patients with and without T2D.

Table 3.

| | No Diabetes (n=40,801) | Diabetes (n=5,598) | p-value |
|---------------------|---------------------------|-----------------------|---------|
| Complications (Any) | 7.4% | 9.5% | <0.001 |
| Infection | 4.9% | 6.3% | <0.001 |
| Cardiac | 1.0% | 1.7% | <0.001 |
| Acute Renal Failure | 0.4% | 0.6% | 0.008 |
| VTE | 1.2% | 1.1% | 0.849 |

T2D Negatively Impacts Trauma Outcomes

- ◆ Logistic regression analysis used to compare patients with and without T2D.

Table 4. Logistic regression:

| | OR for Diabetes | [95% CI for OR] |
|------------------------|-----------------|-----------------|
| Complications (Any) | 1.26 | [1.13, 1.41] |
| Complications (Severe) | 1.29 | [1.15, 1.44] |
| Infection | 1.29 | [1.13, 1.48] |
| SSI | 0.89 | [0.51, 1.57] |
| UTI | 1.35 | [1.10, 1.66] |
| Cdiff | 0.83 | [0.51, 1.35] |
| Systemic sepsis | 1.54 | [1.07, 2.23] |
| Pneumonia | 1.33 | [1.11, 1.59] |
| Cardiac | 1.39 | [1.08, 1.8] |
| Acute Renal Failure | 1.3 | [0.87, 1.96] |
| VTE | 0.97 | [0.73, 1.30] |



T2D Associated With Increased Hospital and ICU Days

◆ Multivariable regression results

Table 4.

| | No Diabetes | Diabetes | p-value |
|----------------|-------------|----------|---------|
| Vent Days | 6.75 | 8.02 | 0.002 |
| ICU Days | 5.45 | 6.40 | <0.001 |
| Length of Stay | 5.69 | 6.35 | <0.001 |

T2D and Poor Outcome Not Associated with Advanced Age

♦ Logistic regression results - Age ≥ 65

| | OR for Diabetes | [95% CI LB for OR] | [95% CI UB for OR] | p-value |
|------------------------|-----------------|--------------------|--------------------|---------|
| Complications (Any) | 1.21 | 1.04 | 1.41 | 0.015 |
| Complications (Severe) | 1.18 | 1 | 1.4 | 0.057 |
| Mortality | 1 | 0.8 | 1.24 | 0.986 |
| Infection | 1.25 | 1.04 | 1.5 | 0.018 |
| SSI | 1.73 | 0.63 | 4.76 | 0.291 |
| UTI | 1.17 | 0.89 | 1.53 | 0.264 |
| Cdiff | 1.07 | 0.56 | 2.06 | 0.835 |
| Systemic sepsis | 1.85 | 1.08 | 3.17 | 0.025 |
| Pneumonia | 1.27 | 0.99 | 1.63 | 0.061 |
| Cardiac | 1.13 | 0.8 | 1.58 | 0.488 |
| Acute Renal Failure | 1.65 | 0.91 | 2.96 | 0.096 |
| VTE | 0.8 | 0.52 | 1.22 | 0.293 |

Sepsis:




A Significant HealthCare Challenge


- ♦ **Major cause of morbidity and mortality worldwide.**
 - Leading cause of death in non-coronary ICUs
 - 11th leading cause of death overall USA
- ♦ **More than 1 million cases annually in the USA.**
- ♦ **More than 500 patients die daily from severe sepsis in the USA.**
- ♦ **Number of cases of severe sepsis or septic shock among all ICU admissions increased every year**


Sands, K.E. *et al. JAMA.* 1997 Jul 16;278(3):234-40.


Miniño AM. *et al. Natl Vital Stat Rep.* 2011 Dec 7;59(10):1-126

Iwashyna, T.J., Angus, D.C. *JAMA.* 2014;311(13):1295-1297.









Delayed Mortality in Severe Sepsis *circa* 2015


Early Recognition, Protocol Bundling, Benchmarking Outcomes, Goal Directed Therapy and Improved Education have just delayed severe sepsis mortality!!

| | ProMISe | ProCESS | ARISE |
|-----------------------|---------|--------------|--------------|
| Outcomes - all groups | | | |
| 28 day mortality | 24.5 | -- | 14.8 - 15.9% |
| 60 day mortality | | 18.2 - 21% | -- |
| 90 day mortality | 29.5% | 30.8 - 33.7% | 18.6 - 18.8% |
| 1 year mortality | | ~40% | -- |

**The ProCESS/ARISE/ProMISe Methodology Writing Committee.,
Intensive Care Med. 2013 October; 39(10).**

Substantial Severe Sepsis Mortality Occurs Long After Hospital Discharge

- ◆ Systematic review of studies reporting long-term mortality and quality-of-life data (>3 months) in patients with sepsis, severe sepsis, and septic shock using defined search criteria.




**Mortality
Increases With
Time
WHY?**

Winters, B.D. et. al. Crit Care Med
2010 Vol. 38, No. 5





HEALTH SYSTEM
UNIVERSITY OF MICHIGAN

A.



B.





T2D and Infection Susceptibility

| Author | Year | Infection type | n | Study design | Main outcome measures | Main findings |
|---------------|------|-------------------------|---------|----------------------------------|-----------------------------------|--|
| Zhao (29) | 2009 | Skin infection | 8,655 | Longitudinal matched control | Incidence of skin infections | Higher risk for skin infections (adjusted OR 2.8) |
| Kornum (57) | 2008 | CAP | 34,329 | Population-based matched control | Pneumonia-related hospitalization | Increased risk for CAP-related hospitalization (RR 1.26 [95% CI 1.21–1.31]) |
| Benfield (32) | 2007 | Infectious diseases | 10,063 | Prospective | Hospitalization, 28-day mortality | Higher risk for infection-related hospitalizations and UTI-related mortality (HR 3.9 [95% CI 1.2–12.7]); no difference in mortality because of sepsis, CAP, skin infection, and other infections |
| Boyko (30) | 2005 | UTI | 1,017 | Longitudinal matched control | Incidence of UTI | Higher risk of UTI (RR 1.8 [95% CI 1.2–2.7]) and antibiotic treatment (RR 2.3 [95% CI 1.3–3.9]) |
| Thomsen (58) | 2004 | Pneumococcal bacteremia | 598 | Matched control | Bacteremia | Higher risk for pneumococcal pneumonia (OR 1.9 [95% CI 1.4–2.6]) |
| Shah (31) | 2003 | Infectious diseases | 513,749 | Matched control | Hospitalization, mortality | Higher risk for hospitalization (RR 2.17 [95% CI 2.10–2.23]) and infection-related mortality (1.92 [1.79–2.05]); no difference in in-hospital mortality (1.05 [0.89–1.01] and 0.84 [0.87–1.01]) |


↑ Infection = ↑ Sepsis

T2D and Sepsis

| Author | Year | Infection type | n | Study design | Main outcome measures | Main findings |
|--------------|------|----------------------------------|--------|-------------------------|--------------------------------------|--|
| Kornum (37) | 2007 | CAP | 29,900 | Population-based cohort | Complications, bacteremia, mortality | Higher mortality rates (1.2 [95% CI 1.1–1.3]), but similar rates of complications and bacteremia; mortality within patients with diabetes increased when initial glucose levels >14 mmol/L in multivariate analysis (adjusted MMR 1.46 [95% CI 1.01–2.12] compared with patients with glucose <6.1 mmol) |
| Thomsen (36) | 2005 | <i>Enterobacteria</i> bacteremia | 1,317 | National registry | Bacteremia, 30-day mortality | Higher risk for bacteremia (OR 2.9 [95% CI 2.4–3.4]) and a trend toward higher 30-day mortality (1.4 [1.0–2.0]) |
| Fine (35) | 1996 | CAP | 33,148 | Meta-analysis | 30-day mortality | Higher risk for mortality (OR 1.3 [95% CI 1.1–1.5]) |

T2D → ↑ Infection = ↑ Sepsis → ↑ Mortality

Sepsis Mortality Rate



Martin, GS, et al. 2003. *NEJM* 348:1546-54.

Hypothesis

Over-arching Hypothesis:

T2D acts as an immune deficiency associated with defects in neutrophil function that directly contribute to bacterial persistence and sepsis mortality.

Diet Induced Obesity (DIO)



Key Points:


C57BL/6J males and controls at least 30 weeks of age to mimic middle aged and older humans

Model of pre-diabetic type 2 diabetes and obesity with elevated blood glucose and impaired glucose tolerance, hyperlipidemia

DIO and Cecal Ligation and Puncture (CLP)




LD₁₀₋₂₀ in C57BL/6 mice at 7 days



Delano, M.J., et. al. *J Exp Med.* 2007. 204(6):1463-74.

Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moldawer LL, Efron PA
Curr Protoc Immunol. 2010 Nov;Chapter 19:Unit 19.13.




DIO vs WT : Bacteria Eradication






n=5 mice/group/time point
ANOVA

Detect Bacteria by Flow


DIO



Lean



DIO vs Lean : Bacteria in peritoneal fluid



n=5 mice/group/time point, ANOVA

Conclusion

- ◆ DIO mice demonstrate overall bacterial persistence compared with Lean controls long after sepsis.
- ◆ What accounts for the bacterial persistence observed in the DIO mice?

Conclusions

- ◆ Trauma patients admitted with T2D experience much higher rates of all, serious, and infectious complications.
- ◆ A better understanding of the physiologic aberrations associated with T2D is necessary to reduce excess morbidity, resource consumption, and improve quality survival in trauma patients with T2D.

Acknowledgements

University of Michigan Collaborators

MTQIP Collaborative

Dr. Mark Hemmila

Anne Cain-Nielsen, MS Biostatistician

Dr. Peter Ward Lab

Dr. Carey Lumeng Lab

Dr. Krishnan Raghavendran Lab



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Questions?
